Psychedelic Drugs

A treatment for depression involving just two doses of psilocybin may have effects that last for years. A new follow-up study found that two-thirds of participants were still in remission five years after their therapy, pointing to its potential durability.

A new meta-analysis suggests LSD has a small but significant positive effect on substance use disorders. The review found inconclusive evidence for its use in treating anxiety or depression, highlighting a split in its therapeutic potential.

People who reported meaningful psychedelic experiences later showed reduced cannabis use and increased psychological flexibility. These findings suggest psychedelics might influence substance use behaviors in lasting ways, particularly when the experience is intense or transformative.

People who regularly use ayahuasca in ceremonial settings may develop more resilient psychological traits and altered emotional brain activity, according to new research exploring how long-term use of this psychedelic affects the mind and brain.

Psilocybin therapy may reduce suicidal thoughts in people with mental health diagnoses, according to a new review in Therapeutic Advances in Psychopharmacology. The analysis combined results from clinical trials and found a modest but significant reduction in suicidal ideation.

In a pilot study, physicians and nurses who took part in mindfulness training combined with psilocybin therapy experienced greater reductions in depression symptoms than those who practiced mindfulness alone, offering preliminary evidence for a new approach to burnout treatment.

A new study in the Journal of Psychopharmacology questions whether psychedelics reliably enhance creative thinking, finding that the effects of an ayahuasca-inspired formulation may actually impair some aspects of creativity while modifying others.

Researchers discovered that tabernanthalog, a non-hallucinogenic analog of psychedelic drugs, can stimulate cortical neuron growth and improve depression-related behavior in mice. The study suggests these effects occur without the gene activity or neurotransmitter surges typically linked to classic psychedelics.

A small pilot study found that a single 25 mg dose of psilocybin led to lasting reductions in depression symptoms among U.S. military veterans with treatment-resistant depression. Half were in remission after six months; 30% remained in remission at one...

Brain recordings suggest that ibogaine slows the brain’s dominant rhythms and reduces signal variability in veterans with traumatic brain injury—patterns that were associated with improved executive function, reduced PTSD symptoms, and lowered anxiety.

A groundbreaking study has revealed that classical psychedelics affect far more than just serotonin. By mapping how 41 compounds interact with brain receptors, researchers challenge long-held assumptions and open new directions for psychedelic science and therapeutic development.

Cancer patients with major depression experienced significant and long-lasting improvements after just one psilocybin session, according to new research. Two years later, many showed continued reductions in depression and anxiety, with some requiring no further treatment or medication.

Psilocybin and MDMA may do more than alter perception. A study in Nature suggests they also reduce fear by targeting a newly identified immune-brain signaling loop, which becomes hyperactive under chronic stress and contributes to heightened fear responses.

A new study comparing near-death experiences with high-dose DMT trips finds striking similarities — and surprising differences — in what people see and feel. The research sheds light on how the brain might shape extraordinary states of consciousness.